Sonoma provides January 2024 investor presentation; no material new financial data

Sonoma Pharmaceuticals, Inc.

Presentation reiterates stabilized HOCl platform for dermatology, wound, eye, nasal, oral, animal health.
Products sold in 55 countries directly or through distribution partners.
Company actively seeking additional distribution partners to expand global reach.

item 7.01 item 9.01

Sonoma Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-24-000168

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.